Bayer secures EU clearance for contrast mammography

By staff writers

January 24, 2023 -- Bayer has secured European Union (EU) regulatory approval for the use of its Ultravist 300 and Ultravist 370 contrast agents for contrast-enhanced mammography examinations.

The exam can be conducted with Ultravist as an adjunct to mammography or an alternative to breast MRI, according to the vendor.

"The approval of Ultravist 300 and 370 in contrast-enhanced mammography gives physicians a new imaging option where conventional mammography might not be enough," said Dr. Konstanze Diefenbach, head of radiology R&D at Bayer.

The clearance expands the company's radiology offerings, including contrast media, injectors, and digital and artificial intelligence, Bayer added.

Copyright © 2023

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking